News

Monday October 12, 2020

12 Oct 2020 – Clinical Study Patient Recruitment Update

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Clinical Study Patient Recruitment Update 101 patients recruited in Phase 2b clinical study of lead asset XF-73 for the prevention of postsurgical […]

Thursday October 1, 2020

01 Oct 2020 – Destiny Pharma welcomes proposed PASTEUR Act in USA

Destiny Pharma welcomes the proposed PASTEUR Act in USA, with financial support ranging from $750 million to $3 billion, to launch new antiinfective products targeting life threatening infections. Click on […]